GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Sertraline - adult oral tablets

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Zoloft

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

ZOLOFT (sertraline hydrochloride) tablets

Product / population
Adult oral tablet examples, not a complete all-indication monograph.
Renal measure
Not specified; verify before use
Starting doses and titration

For adult MDD or OCD, start 50 mg daily. For panic disorder, PTSD or social anxiety, start 25 mg daily. Increase by 25-50 mg no more often than weekly, according to response and tolerance, up to 200 mg/day.

Renal statement

Mild through severe renal impairment does not require a dose change. Renal impairment does not appear to materially alter sertraline exposure.

Safety context

Monitor for clinical deterioration and suicidal thoughts or behavior, particularly in pediatric and young-adult populations. Renal dose neutrality does not eliminate other contraindications or interaction risks.

Source revision: | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=consumer&setid=fda754f6-d0f3-4dce-a17a-927d64f912f7

Scope: Source-read local summary; source-specific recommendations are not automatically interchangeable. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

GlobalRPh RX List

GlobalRPh RX List - ZOLOFT

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Adult oral sertraline; not an automatic treatment dose.

Renal method: Qualitative mild-to-severe impairment; CrCl and HD in supporting PK data.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
Handbook

Renal Drug Handbook, fifth edition

Historical 2019 reference; renal bands retain the book's own method labels.

Renal method: See source.
Retrieved: 2026-09-05

Read local renal result

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeZOLOFT (sertraline hydrochloride) tabletsGlobalRPh RX List - ZOLOFTRenal Drug Handbook, fifth edition
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=consumer&setid=fda754f6-d0f3-4dce-a17a-927d64f912f7

Product and population scope

ZOLOFT oral tablets for adults. The dosing examples cover MDD, OCD, panic disorder, PTSD and social anxiety, not a pediatric or intermittent PMDD regimen.

sertraline-adult:scope · Source section: Selected U.S. label: product title, route, dosage form and indicationRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

ZOLOFT (sertraline hydrochloride) tablets

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. prescribing information · Adult oral tablet examples, not a complete all-indication monograph.

Renal method: Not specified in this summary.
Source date:
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

Starting doses and titration

For adult MDD or OCD, start 50 mg daily. For panic disorder, PTSD or social anxiety, start 25 mg daily. Increase by 25-50 mg no more often than weekly, according to response and tolerance, up to 200 mg/day.

sertraline-adult:dm-fda754f6-d0f3-4dce-a17a-927d64f912f7-1 · Source locator: 2.1, Table 1

Renal statement

Mild through severe renal impairment does not require a dose change. Renal impairment does not appear to materially alter sertraline exposure.

sertraline-adult:dm-fda754f6-d0f3-4dce-a17a-927d64f912f7-2 · Source locator: 8.7

Safety context

Monitor for clinical deterioration and suicidal thoughts or behavior, particularly in pediatric and young-adult populations. Renal dose neutrality does not eliminate other contraindications or interaction risks.

sertraline-adult:dm-fda754f6-d0f3-4dce-a17a-927d64f912f7-3 · Source locator: Boxed Warning; 5.1

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=consumer&setid=fda754f6-d0f3-4dce-a17a-927d64f912f7
Retrieved
2026-09-05
Exact label title
ZOLOFT (sertraline hydrochloride) tablets
DailyMed Set ID
fda754f6-d0f3-4dce-a17a-927d64f912f7
Labeler
Viatris Specialty LLC
DailyMed page updated
2023-08-08
U.S. product identity basis
Exact named product and route appear in the selected U.S. prescription label; current retail availability was not independently assessed.
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
8763882ff444bf9defeabd95f874b4be53e3bed107cc86457aa023e20249b368
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - ZOLOFT

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult oral sertraline; not an automatic treatment dose.

Renal method: Qualitative mild-to-severe impairment; CrCl and HD in supporting PK data.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Mild through severe renal impairment does not require a sertraline dose adjustment according to the source. The selected pharmacokinetic data support similar exposure across the studied renal groups, including hemodialysis. Study doses are not starting-dose recommendations. Hepatic restrictions, interactions and indication-specific titration remain separate.

RDM37-rxlist-sertraline-adult-2b2d09c2ed-C1 · Source locator: Use in Specific Populations: Renal Impairment; Clinical Pharmacology.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/zoloft-drug/
Retrieved
2026-09-07
Renal-function method
Qualitative mild-to-severe impairment; CrCl and HD in supporting PK data.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
902c199feb6527683dc55732292bd9ca1093dace8577ee4f25e62aebb4c46a44
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, fifth edition

Open / share this exact local source

UK Renal Pharmacy Group / Ashley and Dunleavy / CRC Press · Historical 2019 reference; renal bands retain the book's own method labels.

Renal method: Not specified in this summary.
Source date: Not established
Retrieved: 2026-09-05

Historical handbook facts locally summarized; not a current U.S. label or a modern CRRT protocol.

Renal-function and dialysis summary

The book retains normal dosing in its 20-50, 10-20 and <10 mL/min bands. It also retains normal dosing for APD/CAPD, HD, high-flux HDF and CAV/VVHD. It describes removal as unlikely with peritoneal dialysis, absent with HD, and unknown for high-flux HDF and CAV/VVHD.

sertraline-adult:rdh5-912-1 · Source locator: Dose in renal impairment; Dose in renal replacement

Source-specific limits

The normal dose must still be selected for the specific indication. The old CAV/VVHD categories are not an effluent-rate-specific modern CRRT protocol.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page 912; PDF page 931
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
23a290828e6d2c5ab64c287b438a5f0d32ddf9c99927b01f0f3800f6b909dd47

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=consumer&setid=fda754f6-d0f3-4dce-a17a-927d64f912f7
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
handbook us addition
Local text SHA-256
68f4e06a0fd40cf0fbd50e63e3b184e76ad2dd0855f7cc095443ffa73f2b9fed
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report